At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics (Nasdaq: AXSM) presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation ...

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

Jefferies Financial Group started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc. (VZ), The ...

Jefferies initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $200 price target The company currently markets three central ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Axsome Therapeutics ( AXSM – Research Report ), with a price target of $148.00. The company’s shares closed ...